Mammalian Drug Substance Manufacturing

    Trust decades of successful drug development and manufacturing built on mammalian platforms

    Support for Your Mammalian-Based Therapeutics and Vaccines

    There’s good reason mammalian cell expression systems drive many of today’s successful pharmaceutical innovations. They’re not only ideal for high-volume manufacturing of therapeutic proteins and viral vaccines, but they also serve as the platform of choice for next-generation cell and gene therapies. At Emergent CDMO, our mammalian drug substance development and manufacturing teams are ready to work closely with you to deliver a solution honed to your specific needs.

    We help biopharma organizations of all sizes — from small start-ups and research labs to global pharmaceutical companies —successfully manage the development and manufacturing processes required for mammalian cell expression systems to produce a variety of high-quality therapeutic proteins.

    Emergent Bayview Facility

    Trusted to Deliver Excellence in Mammalian Programs

    As your team strives to simultaneously manage productivity, scalability, and cost with your mammalian program, you’ll find the CDMO team at Emergent to be both an understanding and knowledgeable ally. Here’s why clients have come to rely on us:

    • Emergent has hands-on experience in delivering our own mammalian-based vaccines and therapeutics, from preclinical development and regulatory approval to large-scale manufacturing. 
    • We accelerate and provide manufacturing flexibility by incorporating disposables and single-use bioreactors into our manufacturing process.
    • With the technology, facilities, and expertise to support your most demanding projects, we can capitalize on platforms built for both monoclonal antibody and recombinant protein expression. 
    • We can culture and scale up a variety of cell lines (including CHO, HEK293, Vero, PER.C6) for cGMP drug substance manufacturing. 

     

    column connection-reduced

    Emergent Mammalian Platform Technologies and Capabilities

    Technologies Scale Downstream Processing

    Mammalian

    • Monoclonal antibodies (mAbs)
    • Recombinant proteins 

     

    		 Single use bioreactors
    • 50L
    • 200L
    • 500/750L
    • 2 x 2000L 
    • Centrifugation
    • Chromatography
    • Filtration
    • UF/DF

    Let’s Start A Conversation

    Connect now

    Connect with us

    If you are interested in working with Emergent, want to find out more information about our CDMO services, or would like to have us contact you for any reason, please use this web form to send us your information or questions.